Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | Director | June 03, 2026 | June 05, 2026 |
| Climb Bio, Inc.CLYM · Entity 5064 | Director | June 05, 2026 | June 08, 2026 |
| LENZ Therapeutics, Inc.LENZ · Entity 6475 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,300 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 35,500 · Balance 48,300 F1: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2036-06-03 | Direct | 53,250 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 53,250 · Balance 53,250 F2: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
F2: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Climb Bio, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-04 | Direct | 40,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.
LENZ Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.63 · Expires 2036-06-15 | Direct | 22,100 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 22,100 · Balance 22,100 F1: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Jounce Therapeutics, Inc.
Report date May 03, 2023 · Filed May 04, 2023
Section 16 reporting ended · disclosed 2023-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-05-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-05-03 · Other · Disposed 25,751 · Balance 40,267 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effectve as of May 3, 2023 (the "Effective Time"). F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit settleable in Shares (each, a "Company RSU") vested in full, was cancelled and converted into the right to receive (i) the product of (A) the total number of Shares then underlying such Company RSU multiplied by (B) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right for each Share subject thereto. Row 2 · 2023-05-03 · Other · Disposed 40,267 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.36 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-03 · Disposition to issuer · Disposed 206,005 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.02 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-05-03 · Disposition to issuer · Disposed 8,130 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.56 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-05-03 · Disposition to issuer · Disposed 77,235 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.98 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-05-03 · Disposition to issuer · Disposed 97,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-05-03 · Disposition to issuer · Disposed 44,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.55 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-05-03 · Disposition to issuer · Disposed 53,400 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.89 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-05-03 · Disposition to issuer · Disposed 44,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.56 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-05-03 · Disposition to issuer · Disposed 55,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effectve as of May 3, 2023 (the "Effective Time").
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit settleable in Shares (each, a "Company RSU") vested in full, was cancelled and converted into the right to receive (i) the product of (A) the total number of Shares then underlying such Company RSU multiplied by (B) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right for each Share subject thereto.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto.
KINETA, INC./DE
Report date June 30, 2025 · Filed July 02, 2025
Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-06-30 transaction · row 1
1 source rowRow 1 · 2025-06-30 · Disposition to issuer · Disposed 13,794 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F3: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.58 | Direct | 0 |
Reported balance
After 2025-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-30 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F4: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement").
F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA.
F3: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets.
F4: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2021 Filed Jan 22, 2021 18:35 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionCommon Stock | 3,710 | $2.36 | $8,755.60 |
DisclosureSEC source: 0001640455-21-000016 · wf-form4_161135854303039.xml · nonDerivative · entry 3 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 18:35 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionCommon Stock | 6,775 | $0.74 | $5,013.50 |
DisclosureSEC source: 0001640455-21-000016 · wf-form4_161135854303039.xml · nonDerivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 18:35 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionCommon Stock | 3,016 | $0.48 | $1,447.68 |
DisclosureSEC source: 0001640455-21-000016 · wf-form4_161135854303039.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 06:19 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 3,130 | $7.00 | $21,910.00 |
DisclosureSEC source: 0001640455-21-000008 · wf-form4_161036398211616.xml · nonDerivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,881 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F3 · price: Represents the weighted average share price of an aggregate total of 3,130 shares sold in the price range of $6.75 to $7.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 06:19 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 2,697 | $6.76 | $18,231.72 |
DisclosureSEC source: 0001640455-21-000008 · wf-form4_161036398211616.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,011 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: Represents the weighted average share price of an aggregate total of 2,697 shares sold in the price range of $6.66 to $7.02 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 18:05 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 7,200 | $8.06 | $58,032.00 |
DisclosureSEC source: 0001640455-20-000114 · wf-form4_159908432700496.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,708 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019. The Reporting Person exercised no discretion with respect to these transactions. F2 · price: Represents the weighted average share price of an aggregate total of 7,200 shares sold in the price range of $8.00 to $8.10 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 20:31 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 744 | $4.71 | $3,504.24 |
DisclosureSEC source: 0001640455-20-000109 · wf-form4_159779705956306.xml · nonDerivative · entry 3 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,908 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F4 · price: Represents the weighted average share price of an aggregate total of 744 shares sold in the price range of $4.67 to $4.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:31 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 454 | $4.86 | $2,206.44 |
DisclosureSEC source: 0001640455-20-000109 · wf-form4_159779705956306.xml · nonDerivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,652 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F3 · price: Represents the weighted average share price of an aggregate total of 454 shares sold in the price range of $4.72 to $5.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 20:31 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 984 | $4.64 | $4,565.76 |
DisclosureSEC source: 0001640455-20-000109 · wf-form4_159779705956306.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,106 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: Represents the weighted average share price of an aggregate total of 984 shares sold in the price range of $4.55 to $4.75 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 17:24 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 17,400 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001209191-20-039822 · doc4.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,400 Underlying: Common Stock · 17,400 shares Expires 2030-06-29 F1 · derivative.exercise_date: These securities shall vest and become exercisable in equal quarterly installments starting on September 29, 2020 until the option is fully vested and exercisable on June 29, 2021, subject to the Reporting Person continuing to provide services to the Issuer. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:00 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantCommon Stock · Derivative | 53,400 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001640455-20-000019 · wf-form4_158086800255339.xml · derivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,400 Underlying: Common Stock · 53,400 shares Expires 2030-02-03 F1 · derivative.exercise_date: The option will vest quarterly in 16 equal installments following January 1, 2020. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:00 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantCommon Stock | 26,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001640455-20-000019 · wf-form4_158086800255339.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,090 Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 08:54 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 2,624 | $7.78 | $20,414.72 |
DisclosureSEC source: 0001640455-20-000006 · wf-form4_157866443594759.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,390 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: Represents the weighted average share price of an aggregate total of 2,624 shares sold in the price range of $7.62 to $7.88 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 20:58 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 1,018 | $3.92 | $3,990.56 |
DisclosureSEC source: 0001640455-19-000075 · wf-form4_156600349377656.xml · nonDerivative · entry 3 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,014 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F4 · price: Represents the weighted average share price of an aggregate total of 1,018 shares sold in the price range of $3.85 to $4.06 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:58 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 648 | $4.00 | $2,592.00 |
DisclosureSEC source: 0001640455-19-000075 · wf-form4_156600349377656.xml · nonDerivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,032 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F3 · price: Represents the weighted average share price of an aggregate total of 648 shares sold in the price range of $3.94 to $4.09 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:58 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 670 | $4.10 | $2,747.00 |
DisclosureSEC source: 0001640455-19-000075 · wf-form4_156600349377656.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,680 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: Represents the weighted average share price of an aggregate total of 670 shares sold in the price range of $4.02 to $4.18 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 18:02 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantStock Option (Right to Buy) · Derivative | 44,500 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001640455-19-000010 · wf-form4_154940770860401.xml · derivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 44,500 shares Expires 2029-02-01 F1 · derivative.exercise_date: The option will vest quarterly in 16 equal installments following January 1, 2019. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 18:02 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantCommon Stock | 22,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001640455-19-000010 · wf-form4_154940770860401.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,350 Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:25 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 30,600 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007619 · doc4.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,600 Underlying: Common Stock · 30,600 shares Expires 2029-02-01 F1 · derivative.exercise_date: These securities shall vest and become exercisable in equal quarterly installments starting on May 1, 2019 until the option is fully vested and exercisable on February 1, 2020, subject to continued service. Read SEC document |
| August 27, 2018 Filed Aug 28, 2018 17:28 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,700 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001640455-18-000103 · wf-form4_153549169199929.xml · derivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,514 Underlying: Common Stock · 12,700 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the option shares vested and became exercisable on August 26, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter. Read SEC document |
| August 27, 2018 Filed Aug 28, 2018 17:28 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionCommon Stock | 12,700 | $2.36 | $29,972.00 |
DisclosureSEC source: 0001640455-18-000103 · wf-form4_153549169199929.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 17:27 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantCommon Stock | 14,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001640455-18-000099 · wf-form4_153436842609305.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,400 Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 19:06 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,759 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001640455-18-000039 · wf-form4_152089594368204.xml · derivative · entry 3 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,016 Underlying: Common Stock · 3,759 shares Expires 2024-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions. F3 · derivative.exercise_date: The option shares vested and became exercisable in 12 monthly installments from October 9, 2013. Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 19:06 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 5,267 | $25.01 | $131,727.67 |
DisclosureSEC source: 0001640455-18-000039 · wf-form4_152089594368204.xml · nonDerivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions. F2 · price: Represents the weighted average share price of an aggregate total of 5,267 shares sold in the price range of $25.00 to $25.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 19:06 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionCommon Stock | 3,759 | $0.48 | $1,804.32 |
DisclosureSEC source: 0001640455-18-000039 · wf-form4_152089594368204.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:57 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 1,267 | $22.07 | $27,962.69 |
DisclosureSEC source: 0001640455-18-000022 · wf-form4_152046705270757.xml · nonDerivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,508 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trades. F3 · price: Represents the weighted average share price of an aggregate total of 1,267 shares sold in the price range of $21.89 to $22.20 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:57 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 4,000 | $21.21 | $84,840.00 |
DisclosureSEC source: 0001640455-18-000022 · wf-form4_152046705270757.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,775 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trades. F2 · price: Represents the weighted average share price of an aggregate total of 4,000 shares sold in the price range of $20.89 to $21.86 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 18:05 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantStock Option (Right to Buy) · Derivative | 97,500 | $0.00 Strike: $23.98 | $0.00 |
DisclosureSEC source: 0001640455-18-000013 · wf-form4_151787191594300.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2028-02-01 F1 · derivative.exercise_date: The option will vest quarterly in 16 equal installments following January 1, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.